Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

The bromodomain inhibitor OTX015 (MK-8628) has shown anti-lymphoma activity as a single agent in both the preclinical and clinical settings, as well as in vitro synergism with several anticancer agents. Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295419/
https://www.ncbi.nlm.nih.gov/pubmed/27494885
http://dx.doi.org/10.18632/oncotarget.10983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295419/
https://www.ncbi.nlm.nih.gov/pubmed/27494885
http://dx.doi.org/10.18632/oncotarget.10983

Ejemplares similares